Center Point Clinical Services launches site-less CRO
Center Point Clinical Services, creator of the Clinical Trial Research Pharmacist (CTRP) solution, has launched the world's first site-less technology CRO. The site-less CRO model is designed to support the evolving world of clinical trials by empowering study sponsors to de-risk the clinical trial process, increase quality, reduce costs and ensure robust data for regulatory submissions.
Center Point Clinical Services CEO Joe Martinez said, "Current clinical trial models are built around geographical clinical sites, and up to 70% of trial patients may not have convenient access to them. Moreover, clinical trial sites vary greatly in speed of communication, cost to manage patients, and quality of outcomes delivered. The numbers speak for themselves. Clinical trials currently cost approximately $50 billion annually, take six to nine years on average to complete, and may account for almost 40% of total therapy costs."
Martinez continued, "The site-less CRO model enables clinical research to be conducted at an unprecedented scale and scope. Study sponsors are able to reach and maintain excellent communication with trial participants, wherever they are, as well as secure and retain reliable data that can be instantly accessed and shared. Our model provides an insurance policy to 'de-risk' the clinical trial process and empower study sponsors to successfully manage in the new world of patient-centric and direct-to-patient activity. We believe it's the surest way for study sponsors to reduce risk and achieve regulatory and commercialization goals."
Chris Gropp, CEO of Trialogics, said, "We have developed an easy to integrate software program that enables old and new business models to compress the time and cost of executing clinical trials. The team at Center Point Clinical Services is combining our proven technology with their virtual clinical trial business model to disrupt, innovate and improve the efficiency of drug testing. Their goal is simple—test drugs better and at less cost, receive regulatory approval sooner, and increase access for the benefit of the patient."